San Diego, United States
SomaScan, now operating as a part of Illumina, is at the forefront of biotechnology innovation. Founded in 2000 and headquartered in the United States, the company is recognized for its pioneering work in the realm of proteomics, which is crucial in transforming both research and healthcare sectors.
At the core of their technological advancement is the SomaScan® Platform, noted for its unique ability to scale with precision. This positions SomaScan as a leader in the Biotechnology, Health Care, and Medical Devices industries.
In its financial journey, the company received a significant boost with a $375.00M Post-IPO Equity investment in September 2021. Esteemed investors such as Casdin Capital, SoftBank Capital, T. Rowe Price, Janus Henderson, Perceptive Advisors, Novartis Pharma, Illumina, Farallon Capital Management, Counterpoint Global, and Corvex participated, underscoring significant market confidence in SomaScan's offerings and growth potential.
